Oppenheimer’s Equity Division Adds to Sales, Research and Trading

  Oppenheimer’s Equity Division Adds to Sales, Research and Trading

Business Wire

NEW YORK -- May 22, 2013

Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings (NYSE:OPY), is pleased
to announce that its Equity Division has added a number of senior hires in
sales, research, marketing, cash equities and institutional execution

Equity Research – Anna Andreeva and Akiva Felt have joined the firm’s Equity
Research division as Executive Directors and Senior Analysts to cover the
Specialty Retail and Bio and Specialty Pharmaceutical sectors, respectively.
Both analysts possess significant experience in their industries as well as on
Wall Street and will enhance Oppenheimer’s long-standing record of premier
quality research in those key sectors.

Sales – Mark Herrmann has joined the Firm’s West Coast Research Sales team as
an Executive Director to help broaden key regional market penetration. Mark
has covered a variety of significant institutional accounts during his
financial career at firms such as BB&T, Bear Stearns and Paine Webber. An
engineer by training, Mark previously held posts at companies such as Amoco
Corp. and GE. Also joining is Helen Blanaru, Executive Director with
responsibility for sales into Canada. Helen comes to Oppenheimer from Collins
Stewart / Canaccord, and has previously held positions in sales at Merriman,
Curhan & Ford, and as an analyst at Knight Bain.

Trading – Doron Barness joins Oppenheimer as Managing Director on the New York
Sales Trading desk with responsibility for a number of significant
institutional client accounts. His background includes the co-founding of a
hedge fund, WP Asset Management, and 14 years at Goldman Sachs.

Matthew Weitz joins Oppenheimer from Nomura in the newly created role of
Managing Director and Head of Institutional Execution Strategy. With
considerable experience in all aspects of market structure, electronic and
algorithm driven trade and execution needs, Matt will be responsible for
further developing the Firm’s client-facing, electronic trade capture
capabilities and improving the trade execution offering to the mid-tier and
middle-market account base.

Also joining Oppenheimer’s Trading operations are Executive Directors John
Gill and Steve Yung. John brings almost three decades of experience to his
role on the Cash Equities desk as senior trader for the Energy, MLP and
Industrial research segments. Steve, who will assume responsibility for
Specialty Finance/Banking, had previously been with JP Morgan for 12 years.

Capital Markets – Michael Rhea rejoins the Firm as Executive Director on the
Equity Capital Markets Team with responsibility for Small Cap and non-research
covered company marketing. Michael has worked at a variety of distinguished
companies, including a position as one of the first sales representatives at
Soleil Securities. Previously he spent 12 years in institutional research
sales at Oppenheimer.

“We are extremely pleased to be in a position to add such experienced and
talented professionals to Oppenheimer’s Equities Department,” observed John
Hellier, Senior Managing Director and Head of Equities. “These individuals
represent a strengthening of our offering across the platform: in Research
breadth and depth, in sales capability and reach as well as in trade
execution. We continue to search the marketplace for additional high quality,
entrepreneurial professionals who can help the Firm add clients and continue
to increase our share of the Institutional market.”

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer
Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide
a full range of wealth management, securities brokerage and investment banking
services to high-net-worth individuals, families, corporate executives, local
governments, businesses and institutions.

Certain statements in this release may constitute “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve a number of risks, uncertainties and other factors
that could cause actual results to differ materially, as discussed in the
Company’s filings with the Securities and Exchange Commission.


Oppenheimer & Co. Inc.
John Hellier, 212-667-7221
Press spacebar to pause and continue. Press esc to stop.